Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) gained $1.85 to $33.22 last week after submitting an NDA to FDA for deoxycholic acid (ATX-101) to reduce submental (under chin) fat. Kythera plans to submit ex-U.S. regulatory applications by 2Q15.
Medivir AB (SSE:MVIR B) added SEK8.75 to SEK137.5 on Friday after the European Commission approved Olysio simeprevir to treat HCV genotypes 1 and 4 infection in combination with peginterferon, ribavirin and/or Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD).
Medivir and partner Johnson & Johnson (NYSE:JNJ) plan to launch Olysio in the EU next half. J&J already markets the product in